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Abstract
Although low-energy extracorporeal cardiac shock wave (ECSW) therapy represents an attractive non-invasive treatment option for
ischaemic heart disease, the precise mechanisms of its action and influence on the cardiac tissue remain obscure. The goal of this study
was to evaluate the effects of SW application on cardiac function and structure. Four-month-old Fisher 344 rats were subjected to ECSW
therapy. Echocardiographic measurements of cardiac function were performed at baseline and at 1 and 3 months after treatment. Signs of
inflammation, apoptosis and fibrosis were evaluated by immunohistochemistry in the control and treated hearts. ECSW application did not
provoke arrhythmia or increase the troponin-I level. At all time points, the left ventricular ejection fraction and fractional shortening remained
stable. Histological analysis revealed neither differences in the extracellular matrix collagen content nor the presence of fibrosis; similarly,
there were no signs of inflammation. Moreover, a population of cardiac cells that responded eagerly to ECSW application in the adult heart
was identified; c-kit–positive, Ki67-positive, orthochromatic cells, corresponding to cardiac primitive cells, were 2.65-fold more numerous
in the treated myocardium. In conclusion, non-invasive ECSW therapy is a safe and effective way of activating cardiac stem cells and
myocardial regeneration. Because many factors influence cellular turnover in the ischaemic myocardium during the course of ischaemic
heart disease, cardiac remodelling, and heart failure progression, studies to identify the optimal treatment time are warranted.
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Introduction
According to the current understanding of cardiac biology, car-
diomyocytes, smooth muscle and endothelial cells are continu-
ously renewed to preserve heart function throughout life [1].
Myocardial ischaemia and infarction are the results of coronary
vessel diameter reduction or occlusion that affect all cardiac cells,
which leads to the impairment of their function or death by apop-
tosis or necrosis. This process, in turn, can lead to heart failure.
Over 14 million people in Europe suffer from heart failure. This
number is forecast to increase to 30 million by the year 2020 [2].
Contrary to public belief, heart failure is far more common than
most tumours, including breast, cervical and intestine cancers. If
new treatment options are not implemented soon, society will
have to cope with the burden of increasing hospitalizations and
escalating economic costs, two factors acceptable neither for car-
diologists nor for national health services.
With the lowering of SW energy, new indications for SW use
have come to light. Although destructive at about 10 times higher
energy flux density, SWs are regenerative at 0.1 mJ/mm2 [3].
Their application has been tested in animal models of ischaemic
heart disease [4–6] and in patients with angina pectoris, where
ECSW therapy alleviated symptoms and improved myocardial per-
fusion [7–10]. While the precise mechanisms of SW action and
the influence of SWs on cardiac tissue remain obscure, ECSW
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therapy seems to offer great promise for patients with ischaemic
heart disease and represents an attractive non-invasive treatment
option. However, SW can cause non-selective tissue damage and
as such may induce an injury-and-repair process in the
myocardium, even at the low energy used in ECSW treatment. This
process can be expected to result in muscle cell loss, interstitial
fibrosis and vascular sclerosis [11]. Consequently, a reasonable
demand for safety and mechanism studies has been forcefully
expressed by practicing cardiologists.
The clinical benefits derived from ECSW therapy have been
attributed to the improvement of myocardial blood flow and
enhanced angiogenesis [6]; however, in light of the relevant cardiac
biology, it is inconceivable that the effects of SW should be limited
to the induction of angiogenesis and endothelial progenitor cell 
activation. The shear stress on cell membranes provoked by SWs
results in cell membrane permeabilization and in the activation of
membrane receptors and intracellular signal transduction pathways
[12]. This action could affect all of the cardiac cells responsible for
cardiac regeneration, including cardiac stem cells and primitive cells
that represent the progenitors and precursors of cardiac cell line-
ages (cardiomyocytes, smooth muscle and endothelial cells).
The aim of the study was to evaluate the safety of ECSW appli-
cation on the adult heart and its effects on cardiac tissue function
and morphology. Moreover, the histological analysis of treated
hearts allowed us to identify a population of cardiac cells that
responds eagerly to SW application in the adult heart.
Materials and methods
Study protocol
Four-month-old Fisher 344 male rats were divided randomly into control 
(n  10) and ECSW-treated (n  10) groups. The latter was subjected to
echocardiography-guided ECSW therapy. An electrocardiography tracing
was recorded during the treatment to identify signs of arrhythmia. The car-
diac troponin-I (cTnI) concentration was measured in plasma obtained
from control and treated animals at 1 hr after the first ECSW application.
Echocardiographic measurements of the left ventricular ejection fraction
and fractional shortening were performed at weeks 5 and 13 in the control
and treated animals. Five animals in each group were sacrificed at week 
5 and at week 13, and animal hearts were excised and processed for his-
tological study. The protocol was approved by the local ethics committee,
and all experiments were supervised by the Laboratory Animal Care
Committee of the Second University of Naples.
ECSW treatment
Animals in the control and treated groups were anaesthetized with 1.5%
inhaled isoflurane and became unresponsive to a moderate pain stimulus
while still normally breathing spontaneously. This anaesthetic regimen
does not affect the left ventricular dimensions or ejection fraction in
healthy animals [13]. Treatment was performed using a Duolith Vet compact
shock wave unit that electromagnetically generates focused SWs (Storz
Medical AG, Tägerwilen, Switzerland). A total of 100 shots were delivered
at a total energy flux density of 0.25 mJ/mm2 during every treatment ses-
sion, with three sessions in 1 week. A specially designed hand-piece
enabled the mechanical adjustment of the therapeutically effective depth of
SW penetration in rats.
Echocardiography
All measurements were performed with a 25-MHz linear transducer coupled
to a high-resolution Micro-Ultrasound System (Vevo 770; VisualSonics,
Inc., Toronto, Canada). Serial M-mode echocardiographic images were
taken in the short axis view at the level of the papillary muscles. Images
were stored digitally for offline analysis. The end-diastolic and end-systolic
left ventricular diameter and posterior wall thickness were measured, and
fractional shortening and ejection fraction were calculated.
Cardiac troponin-I measurement
A high-sensitivity ELISA kit (Life Diagnostics, Inc., West Chester, PA, USA)
was used for the determination of cTnI in rat plasma. Samples were incu-
bated simultaneously with two different affinity-purified antibodies, includ-
ing an antibody for solid phase immobilization and a horseradish peroxidase
(HP)-conjugated antibody. Incubation was performed in microtitre wells on
a plate shaker for 1 hr at room temperature. After washing, a solution of
tetramethylbenzidine was added for 20 min. The reaction was stopped by
the addition of HCl, and the absorbance was measured at 450 nm with a
microplate reader (ELx800; BioTek, Winooski, VT, USA). A standard curve
was constructed by measuring the mean absorbance of the serially diluted
cTnI standard. All samples were assayed in triplicate and the actual concen-
tration of cTnI (g/l) was determined from the standard curve.
Tissue staining
Rats were anaesthetized with ketamine (100 mg/kg, i.p.). The abdominal
aorta was cannulated with a polyethylene catheter filled with 0.2M PBS 
(pH 7.4) and 100 IU/ml heparin. In rapid succession, the heart was
arrested in diastole by injection of 100 mM cadmium chloride through the
aortic catheter, the thorax was opened, and the heart was perfusion-fixed
with 10% (v/v) neutral buffered formalin. The hearts were dissected and
post-fixed for 90 min. at room temperature. Cardiac tissue was embedded
in paraffin, sliced into serial 4-m-thick sections and placed on poly-L-
lysine-coated glass slides.
Slides were deparaffinized, rehydrated and stained with haematoxylin
and eosin, Masson’s trichrome stain or Picrosirius red stain, in accordance
with standard practices [14]. Alternatively, sections were immunostained
with primary antibodies against Ki67 (1:600, rabbit polyclonal; Novocastra
Laboratories Ltd., Newcastle upon Tyne, UK), c-kit (1:10, rabbit polyclonal)
and Flk-1 (1:25, mouse monoclonal, both from Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and detected with indirect an immunoperoxidase
technique by employing the IHC Select Immunoperoxidase Secondary
Detection System (DET-HP1000; Millipore, Temecula, CA, USA). To identify
mast cells in tissue samples, deparaffinized sections were stained with 0.2%
toluidine blue for 5 min., washed, quickly dehydrated and cover-slipped for
observation. Negative controls (i.e. isotype-matched non-specific antibodies)
were included for each staining. Microscopic analysis was performed with
a Leica DMLB microscope (Leica Microsystems, Wetzlar, Germany).
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Pictures were taken in bright field with a digital camera (Leica DC200; Leica
Microsystems) connected to the microscope.
Apoptosis evaluation
Apoptotic cells were detected in situ by labelling and detecting DNA strand
breaks in the TUNEL assay. Paraffin-embedded tissue sections were
deparaffinized and pre-treated with proteinase K (20 g/ml). Sections were
incubated with terminal deoxynucleotidyl transferase in the presence of
digoxigenin-labelled and -unlabelled nucleotides, which marked the free
3’OH DNA termini in situ. This step was followed by incubation with an
anti-digoxigenin antibody conjugated to a peroxidase reporter molecule (all
reagents were provided by Millipore, Billerica, MA, USA). Microscopic
analysis was performed with a Leica DMLB microscope, and pictures were
taken in bright field with a digital camera connected to the microscope.
Statistical analysis
All numerical data are presented as mean  S.E.M. Statistical differences
between groups were evaluated with Student’s two-tailed unpaired t-test
(paired t-test was used for the cTnI concentration comparison). A P-value
of  0.05 was considered significant.
Results
ESCW application did not provoke arrhythmia 
or myocardial necrosis
Shock waves generate a physical force that may influence the mem-
brane action potential. This process in turn may interfere with con-
tractile stimuli generation in the nodal cells and conduction in the
Purkinje fibres and cardiomyocytes. Therefore, we secured a direct
electrocardiographic tracing during the ECSW application. Even if
not R wave–triggered (due to the high physiological frequency of
heartbeat in rats), the ECSW application did not induce arrhythmia.
The laboratory measurement of cTnI concentration is a highly
specific marker of acute myocardial infarction and myocardial
injury associated with rhabdomyolisis, pulmonary embolism,
myocarditis and acute pericarditis [15], all of which are possible
complications of ECSW application. High-sensitivity ELISA
revealed stable TnI levels of 0.155  0.0005 g/l and 0.158 
0.002 g/l (n 4, P 0.05) at baseline (before ECSW treatment)
and at 1 hr after 100 shots at 0.25 mJ/mm2, respectively (Fig. 1).
ECSW therapy did not induce functional 
or morphological damage to the heart
Echocardiographic evaluation of the control and treated rats at
weeks 5 and 13 revealed preserved cardiac left ventricular ejection
fraction and fractional shortening after treatment at both time
points (Table 1).
Collagen plays a vital role in maintaining structural integrity and
in determining tissue function. In the heart, both decreases in [16]
and excess accumulations of collagen [17] can be detrimental. We
used Masson’s trichrome and Picrosirius red stains (Fig. 2C–F) to
visualize the fine collagen fibres in the myocardium of control and
ECSW-treated animals. Neither control nor ECSW-treated animals
manifested cardiac fibrosis throughout the study period. The
myocardial collagen content was similar in control and treated ani-
mals up to 3 months after ECSW treatment. In terms of possible
endothelial damage, there was no thickening of the blood vessel
intima. Local subepicardial vasculogenesis was observed in treated
rats in regions corresponding to the transthoracic SW application
zone; however, inflammatory interstitial infiltration was not
observed in the cardiac tissue of treated animals (Fig. 2A and B).
Several mechanisms of SW action, such as direct mechanical
stress or paracrine action of the factors secreted from damaged or
activated cells, may lead to cellular apoptosis. In the heart,
increased myocyte apoptosis is associated with the progression of
cardiac failure of both ischaemic and non-ischaemic origin [18].
After ECSW therapy in rats, the percentage of apoptotic cells (Fig. 3)
Table 1 Echocardiographic characteristics of control and SW-treated
rats
5 Weeks 13 Weeks
Control SW-treated Control SW-treated
(n  5) (n  5) (n  5) (n  5)
EF (%) 70  3 71  5 59  4 61  7
FS (%) 47  5 48  6 41  2 40  6
EF: ejection fraction; FS: fractional shortening. Mean  S.E.M. No sig-
nificant differences were seen between the groups at any time point.Fig. 1 Application of ECSW does not induce myocardial necrosis. High-
sensitivity ELISA was used to determine the actual concentration of cTnI in
plasma collected from rodents at baseline and at 1 hr after the application
of 100 shots of SW at 0.25 mJ/mm2. The cTnI levels remained stable after
the treatment (n  4, P  0.45).
J. Cell. Mol. Med. Vol 16, No 4, 2012
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was similar in control and treated rats at 5 weeks (0.33  0.019%
and 0.37  0.037%, respectively; n 4, P 0.35) and at 13 weeks
(0.35  0.024% and 0.39  0.023%, respectively; n  4, P 
0.28). Remarkably, all apoptotic cells were non-myocytes.
ECSW treatment resulted in the activation 
of c-kit–positive cardiac cells
C-kit (also known as CD117)-positive cardiac cells represent a
population of cardiac stem cells and progenitors/precursors of
cardiac cell lineages in the developing [19] and adult heart [20]. In
contrast to control hearts, immunohistochemical analysis of the
rat myocardium at 3 months after ECSW treatment revealed the
presence of c-kit–positive cell clusters (Fig. 4A). ECSW treatment
increased the number of c-kit–positive cells 2.65-fold compared 
to control hearts (279.1  52.86 versus 105.4  15.25 c-kit–
positive cells/100 mm2; n  4, P  0.05).
Because a sub-population of c-kit–positive cells represents
Fig. 2 ECSW application does not induce
structural damage to the heart. Histochemistry
and immunohistochemistry methods were
used to evaluate the morphology of cardiac tis-
sue in control and treated animals at 3 months
after ECSW application. Haematoxylin and
eosin staining revealed no signs of inflamma-
tory infiltration in control (A) or SW-treated
hearts (B). Masson’s trichrome (collagen in
blue; C, D) and Picrosirius stainings (collagen
in red; E, F) revealed no signs of fibrosis in
control (C, E) or SW-treated hearts (D, F).
Scale bar: 100 m.
Fig. 3 ECSW therapy did not provoke apoptosis of the cardiac cells. The
percentage of apoptotic cells, as evaluated by the TUNEL assay, was 
similar at 5 weeks (n  4, P  0.35) and 13 weeks (n  4, P  0.28) in
control and treated rats.
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endothelial progenitor cells [21], we identified cells expressing the
vascular endothelial growth factor receptor (VEGFR) Flk-1 in the
clusters of cells detected after ECSW treatment (Fig. 4B). The vas-
cular density increased from 380.75  13.49/mm2 in the control
to 428.00  14.71/mm2 in the SW-treated hearts (n  4, P 
0.05). Moreover, Ki67 staining, which marks cells in the G1, S, G2,
and M phases of the cell cycle, revealed that the fraction of actively
cycling c-kit–positive cells was 1.56-fold higher in treated animals
compared to control (55.70  1.34% versus 35.74  2.93%; 
n  4, P  0.05) at 3 months after SW application (Fig. 4C).
The possibility that the observed c-kit–positive cells were car-
diac mastocytes was ruled out by a toluidine blue staining. The
clusters of c-kit–positive cells stained blue, while mastocytes were
extremely rare among myocardial cells and displayed unique mor-
phological features, including the presence of fine metachromatic
granules in the cytoplasm (Fig. 5).
Fig. 4 ECSW application increases the number of cardiac primitive cells.
Clusters of c-kit-positive, Ki67-positive and Flk-1-positive cells were
observed in the myocardium of ECSW-treated animals only. Representative
images of the serial sections of cardiac tissue stained by immunohisto-
chemistry for c-kit (A), Flk-1 (B) and Ki67 (C) are shown. Scale bar: 50 m.
Fig. 5 Toluidine blue staining excludes the presence of mastocytes in the
activated cell clusters. Representative images with a mastocyte (A) demon-
strating typical metachromatic granules in the cytoplasm and a cluster of
orthochromatic c-kit-positive cells (B). Scale bar: 100 m.
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Discussion
The rapid progression from orthopaedics, where low-energy SWs
are used to treat non-union fractures and degenerative diseases of
the connective tissue, to cardiology; from bench, at which the
exact mechanisms of SW action on cardiac tissue have not been
satisfactorily elucidated, to bedside; from animal studies, which
have been limited mostly to the observation of functional out-
comes, despite the availability of tissue samples for further histo-
logical analysis, to clinical trials, all testify of the urgent need for
new treatment options for heart failure patients.
The concept of cardiac regeneration first emerged when stem
cells were described in the human heart. These cells express the
stem cell factor receptor c-kit, are multipotent, and generate myocar-
dial, endothelial and smooth muscle lineage cells [22]. Two hypothe-
ses have been suggested for the origin of stems cells (e.g. that 
circulating stem cells home to the heart from other tissues, or that
stem cells are developmental residents in the heart), although the
true origin remains to be established. Both hypotheses give rise to
different regenerative approaches, including bone marrow/peripheral
blood–derived cell transplantation and local activation of cardiac
intrinsic regenerative properties by growth factor injection.
Although a precise mechanism of action remains unknown,
cardiac SW therapy seems to influence both the peripheral and
resident cardiac stem cell pools. A recent experimental study
demonstrated that the pre-treatment of ischaemic tissue with low-
energy SW facilitates the recruitment of circulating progenitor
cells into chronic ischaemic tissue [23]. In addition to VEGFR up-
regulation [24], stromal cell–derived factor-1 (SDF-1) up-regula-
tion was suggested as the predominant mechanism for the
enhanced recruitment of endothelial progenitor cells after SW
treatment. If SDF-1 becomes up-regulated by SW treatment, other
cytokines and growth factors might be up-regulated in the
ischaemic target tissue, which would enhance the activation of
resident stem cells. Indeed, low-energy SW treatment of c-
kit–positive adult human cardiac primitive cells in vitro enhances
the proliferation of cells and the expression of markers of car-
diomyocyte, endothelial and smooth muscle cell lineages [25].
Similarly, evidence for cardiac stem cell activation was observed
in vivo in this study: in contrast to control hearts, the number of
c-kit–positive cycling cells increased in the treated myocardium.
This novel finding forms a foundation for the use of ECSW for the
activation of myocardial regeneration.
Ischaemic heart remodelling and heart failure progression are
closely related to the increased concentration of factors such as
oxidants, nitric oxide, angiotensin II and catecholamine, which can
trigger the apoptosis of cardiomyocytes [26]. A rapid enhance-
ment of endothelial nitric oxide synthase activity and an increase
in nitric oxide production have been observed in vitro as a conse-
quence of SW application [27]. This effect presumably represents
a local and transitory anti-inflammatory action of SWs, but may
contribute to the apoptosis of cardiac cells. Similarly, SWs may
influence the cell membrane potential and interfere with contrac-
tile stimuli generation and propagation in the conduction system
cells and cardiomyocytes.
Given the lack of safety and mechanism studies, it remains
uncertain whether the benefits of ECSW application outweigh its
risks. Accordingly, we evaluated the effects of low-energy SW
application on cardiac tissue function and structure. ECSW treat-
ment did not provoke arrhythmia or increase the cTnI level.
Histological analysis revealed neither differences in the extracellu-
lar matrix collagen content nor the presence of fibrosis. Moreover,
the SWs did not contribute to the apoptosis of cardiac cells in
treated hearts in vivo, and there were no signs of inflammation at
3 months after ECSW treatment.
Fibrosis is a hallmark of the cardiac remodelling that leads to
increased myocardial stiffness and cardiac dysfunction. Because
this condition may represent an earlier inflammation of the cardiac
tissue or cardiac cell loss [28], its absence at the 3-month time
point indicates that no relevant damage was inflicted in the cardiac
tissue following ECSW application. This result is particularly evi-
dent in our setting, because the cTnI increase in the rodent heart
is directly and constantly correlated with histological damage to
the cardiac tissue. A normal cTnI concentration precludes cardiac
tissue damage and vice versa [29]. The absence of histological
indices of cardiac lesions in our study, independent of the meas-
urement time of the cTnI concentration, indicates that there was
no myocardial tissue damage at any time point. Accordingly, the
heart function, as evaluated by the echocardiographic measure-
ment of left ventricular ejection fraction and fractional shortening,
remained stable at all time points in the SW-treated rats.
In conclusion, non-invasive ECSW therapy is a safe and effec-
tive way to activate cardiac stem cells and myocardial regenera-
tion. With regards to its application in ischaemic heart disease,
the optimal treatment time should be established. It may be that
ischaemia-induced cardiac remodelling provokes changes that
limit the responsiveness of cardiac primitive cells to SW treat-
ment, while cardiac tissue at the early stages of coronary artery
disease may represent the best soil for plant growth: namely, a
responsive environment in which the cardiac stem cells activated
by ECSW therapy can bloom and thereby regenerate the
ischaemic heart.
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